Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 7 | 11 |
| 2004 | 4 | 2 | 6 |
| 2005 | 7 | 13 | 20 |
| 2006 | 3 | 7 | 10 |
| 2007 | 7 | 7 | 14 |
| 2008 | 5 | 6 | 11 |
| 2009 | 4 | 8 | 12 |
| 2010 | 6 | 10 | 16 |
| 2011 | 11 | 12 | 23 |
| 2012 | 5 | 5 | 10 |
| 2013 | 6 | 8 | 14 |
| 2014 | 14 | 13 | 27 |
| 2015 | 22 | 18 | 40 |
| 2016 | 15 | 18 | 33 |
| 2017 | 11 | 7 | 18 |
| 2018 | 14 | 16 | 30 |
| 2019 | 13 | 22 | 35 |
| 2020 | 17 | 20 | 37 |
| 2021 | 11 | 10 | 21 |
| 2022 | 1 | 7 | 8 |
| 2023 | 2 | 3 | 5 |
| 2024 | 6 | 8 | 14 |
| 2025 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
-
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced. NAR Cancer. 2025 Jun; 7(2):zcaf015.
-
Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data. Cancer Treat Res Commun. 2025; 43:100921.
-
Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. Immunity. 2025 Apr 08; 58(4):909-925.e7.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.
-
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
-
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2025 Feb 03; 31(3):479-490.
-
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Jan-Feb; 25(2):149-159.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 01 07; 15(1):1061.
-
FOXM1-Cx31 Axis Drives Pancreatic Cancer Stem Cell-Like Properties and Chemoresistance. Mol Carcinog. 2025 Mar; 64(3):565-579.